JIPOAd
  • Users Online: 183
  • Print this page
  • Email this page
 
REVIEW ARTICLE
Ahead of Print

Extracellular signal-regulated kinase (ERK) inhibitors in oncology clinical trials


1 Rice University, Denver, CO, USA
2 University of Colorado – Denver, Denver, CO, USA
3 Sarah Cannon Research Institute at HealthONE, Denver, CO, USA

Correspondence Address:
Gerald S Falchook,
Sarah Cannon Research Institute at HealthONE, 1800 Williams Street, Suite 300, Denver, CO 80218
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JIPO.JIPO_17_18

The mitogen-activated protein kinase (MAPK) pathway consists of the series of protein kinases RAS-RAF-MEK- Extracellular signal-regulated kinase (ERK), and its function is important to cell proliferation, differentiation, motility, and survival. Certain mutations in the pathway, such as KRAS or BRAF V600 mutations are associated with cancer. Inhibitors of this pathway, including some MEK and BRAF inhibitors, are already being used in the clinic, but a variety of selective ERK inhibitors are still being tested in clinical studies. To date, common adverse events associated with ERK inhibitors include diarrhea, nausea, fatigue, and rash. ERK inhibitors have demonstrated preliminary antitumor activity and may be most effective against cancers with RAS, RAF, or MAPK pathway alterations. This review discusses the MAPK pathway, the biological rationale for ERK inhibitors, and clinical trials involving ERK inhibitors.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Chin HM
    -  Lai DK
    -  Falchook GS
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed17    
    PDF Downloaded5    

Recommend this journal